Thank you for your message about A Study of Nusinersen Among Participants With Spinal Muscular Atrophy Who Received Onasemnogene Abeparvovec. You must verify your email address to receive further communication about this trial. Please check your email for a verification message.
We're sorry, your verification code has expired. Please submit another form using the button below to receive communications about your preferred clinical trial study.